News | November 14, 2025
Hormone therapy for menopause gets green light from FDA
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Enabling a new era in minimally invasive obesity treatment across Europe
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Subscribe To Our Newsletter & Stay Updated
